| Similar Articles |
|---|
 |
The Motley Fool
April 25, 2005
Charly Travers |
Where Is QLT going? The drug maker's upcoming conference call needs to address the question. Shares are down 30% since the beginning of the year. Can QLT turn this around?   |
The Motley Fool
October 26, 2006
Brian Lawler |
QLT Quickly Losing Traction The biotech company gets hammered by a competitor's superior product. There was one bright spot in the quarter for QLT, though. Investors, take note. |
The Motley Fool
October 29, 2007
Brian Lawler |
QLT in a Rut or Ready for a Comeback? QLT updates investors on its top drugs. |
The Motley Fool
August 31, 2004
Charly Travers |
Hidden Value With QLT The market might overlook the drug maker's promising programs. Over the next six months, biotech investors should keep an eye on this one. |
The Motley Fool
February 26, 2007
Brian Lawler |
Is QLT the Comeback Kid? The Canadian drugmaker updates investors on its outlook for 2007. |
The Motley Fool
June 10, 2008
Brian Lawler |
Allergan's Unblemished Deal Acquiring a niche acne drug from QLT provides clarity for both companies. |
The Motley Fool
July 5, 2006
Brian Lawler |
Stay Away From QLT Competitive pressure on its top drug makes this company one investors should avoid. |
The Motley Fool
February 23, 2005
Charly Travers |
QLT Is Still a Value The market's concerns mean this Canadian drug company is being offered up at a great price. |
The Motley Fool
March 29, 2005
Charly Travers |
A Biotech Value Play Sometimes you have to invest against the grain. Take a look at Canadian drug company QLT. |
The Motley Fool
November 29, 2007
Brian Lawler |
QLT Goes on the Block QLT announced yesterday that it's in the preliminary stages of exploring a sale. |
The Motley Fool
September 12, 2006
Brian Lawler |
Those Buybacks at QLT Is the biopharmaceutical repurchasing shares to make itself more attractive for an acquisition? Investors, take note. |
The Motley Fool
August 31, 2007
Brian Lawler |
QLT Gets Reformulated Drug developer QLT announced that an EU approval will open new markets for the cancer drug that could edge out the competition by lowering overall medical costs. |
The Motley Fool
March 18, 2008
Brian Lawler |
QLT's Blemished Aczone Clears Up A more lenient label from the FDA is good news for this drugmaker. |
The Motley Fool
April 24, 2007
Brian Lawler |
Is the Worst Over for QLT? The biopharma announces another dismal quarter of declining sales for its top compound. |
The Motley Fool
January 22, 2007
Brian Lawler |
QLT's Sagging Sales The drug developer's macular degeneration treatment has seen declining sales. And as sales fall, so too does the percent of profits that QLT keeps. Investors, take note. |
The Motley Fool
June 8, 2007
Brian Lawler |
QLT Eats Itself The beleaguered specialty pharmaceutical opens up another share buyback plan. |
The Motley Fool
January 21, 2005
Charly Travers |
Seeing the Value in QLT A narrow-minded market could be creating a great drug value. |
The Motley Fool
June 15, 2004
Charly Travers |
QLT Swallows Atrix Atrix Laboratories has been purchased by Canadian drug company QLT. For Atrix shareholders, the timing of this deal must be incredibly frustrating. |
The Motley Fool
July 17, 2007
Brian Lawler |
QLT Stays the Course Sales of QLT's Visudyne, a drug to treat macular degeneration, continue to plummet due to competition. QLT plans to try to resuscitate. |
The Motley Fool
March 31, 2008
Brian Lawler |
A Good Mix for QLT QLT takes one step closer toward a winning combination for those who suffer from macular degeneration. |
The Motley Fool
January 22, 2007
Brian Lawler |
Another Busy Year in Store for Novartis Trying to place a value on Novartis is a tough thing to do now with so many important drugs awaiting regulatory review and its addiction to acquisitions and divestitures making financial comparisons between the years tough. |
The Motley Fool
July 16, 2010
Brian Orelli |
A Positive Sign for Pharma Earnings Season Strong first-half results drove Novartis to increase its sales guidance for the year. |
The Motley Fool
January 3, 2005
Rich Duprey |
Eying Profits in Eye Sight Macular degeneration is proving to be a field with eye-popping potential. Manufactured by Pfizer and Eyetech, a tiny biotech that went public early last year, Macugen was recently approved by the FDA. |
The Motley Fool
August 31, 2005
Stephen D. Simpson |
Sanofi-Aventis: A Mix of News The company gave investors a lot of information for the second quarter, with not all of it positive. |
The Motley Fool
April 20, 2007 |
Armor's Profits Pierced: Fool by Numbers The maker of military vehicles and armor released first-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
April 1, 2004
Charly Travers |
Atrix Batting 1.000 Atrix Laboratories' drugs have breezed past the Food and Drug Administration. |
The Motley Fool
May 4, 2007 |
Blackbaud Blasts Ahead: Fool by Numbers The software maker for nonprofit organizations released first-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
April 25, 2007 |
Corporate Executive Board Can't Please the Street: Fool by Numbers The business consultant released earnings for the first-quarter 2007: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
April 24, 2006
Tim Beyers |
Earning the Cat's Meow in Q1: Fool by Numbers Caterpillar released first-quarter earnings 2006: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Checkup... |
The Motley Fool
April 27, 2006
Tim Beyers |
Akamai's Broken Record: Fool by Numbers The content delivery specialist released first-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Checkup... |
The Motley Fool
March 16, 2005
Cliff Malings |
Nice of You to Notice Novartis The Street finally pays attention to a longtime pharma winner on news of a major generic-drug acquisition. |
The Motley Fool
December 21, 2006 |
Accenture Sitting Pretty: Fool by Numbers The company released first-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
April 27, 2007 |
3M Posts It: Fool by Numbers The industrial conglomerate released first-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
April 22, 2008
Brian Lawler |
No Earnings Holes for Novartis The drugmaker holds its own in Q1; all three of its major divisions experienced sales growth, even in the face of some tough comparisons to last year. |
The Motley Fool
September 8, 2006
Anders Bylund |
National Semi Looking Ahead: Fool by Numbers National Semiconductor released first-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
March 21, 2007
Ryan Fuhrmann |
Adobe's Acrobatic Quarter: Fool by Numbers The creative software firm released first-quarter 2007 results: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
February 8, 2007 |
Tyco Teeters: Fool by Numbers The conglomerate released first-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
April 23, 2007 |
Fueled by Manpower: Fool by Numbers The staffing firm released first-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
May 9, 2007 |
No Rx Needed for CVS/Caremark: Fool by Numbers The retail pharmacy released first-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
October 26, 2006
Tim Beyers |
1-800-Flowers Smells Sweeter: Fool by Numbers The Internet florist released first-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Checkup... |
The Motley Fool
July 23, 2007 |
Satyam Outsources Profit: Fool by Numbers Appreciating Indian currency hurts Satyam Computer, the global consulting and IT services company. |
The Motley Fool
September 26, 2006
Ryan Fuhrmann |
Nice Quarter by Nike: Fool by Numbers The company released first-quarter 2007 earnings. Here's a summary of the high-level numbers that caused a major move int the stock price: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... etc. |
The Motley Fool
April 25, 2007 |
Edwards Lifesciences Survives: Fool by Numbers The cardiovascular disease treatment company released first-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
June 7, 2006
Stephen D. Simpson |
Novartis Can't Say No The Swiss drug giant signs more deals to boost its pipeline. Investors, here is a strong company in a weak sector that's still somewhat undervalued -- not exactly the worst story of the week. |
The Motley Fool
June 1, 2007 |
Big Lots, Large Numbers: Fool by Numbers The discount retailer released first-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
May 9, 2007 |
InterDigital Tunes Up: Fool by Numbers The wireless technology developer released first-quarter earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
May 2, 2007 |
Under Armour Protects Its House: Fool by Numbers The specialty clothing maker released first-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
April 20, 2007
Emil Lee |
Capital One's Credit Hassles: Fool by Numbers The financial firm released first-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... |
The Motley Fool
April 23, 2007 |
Honeywell Sweetens Up: Fool by Numbers The diversified manufacturer released first-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
February 21, 2007 |
HP Hits but Still Misses: Fool by Numbers The computer maker released first-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
